Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $26.0900 (-3.73%) ($25.4100 - $27.2600) on Mon. Mar. 19, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.52% (three month average) | RSI | 58 | Latest Price | $26.0900(-3.73%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -2% a day on average for past five trading days. | Weekly Trend | ADMS advances 3% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(24%) IBB(22%) IWM(18%) IWO(18%) QQQ(18%) | Factors Impacting ADMS price | ADMS will decline at least -2.26% in a week (0% probabilities). VIXM(-12%) UNG(-10%) BNDX(-9%) UUP(-7%) TLT(-6%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.26% (StdDev 4.52%) | Hourly BBV | 0 () | Intraday Trend | -3.1% | | | |
|
Resistance Level | $26.23 | 5 Day Moving Average | $26.59(-1.88%) | 10 Day Moving Average | $26.68(-2.21%) | 20 Day Moving Average | $26.23(-0.53%) | To recent high | -38.8% | To recent low | 7.1% | Market Cap | $738m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |